MedTrace Logo

VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension

NCT01889966 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-04-28

No results posted yet for this study

Summary

Sildenafil is a selective pulmonary vasodilator; in patients with a special kind of pulmonary hypertension it is approved for treatment. The trial seeks to find out, whether the acute response to this treatment (= vasoreactivity testing) given intravenously is effective and allows prediction of therapy success during a following oral treatment.

Conditions

  • Pulmonary Hypertension Associated With Connective Tissue Disease

Interventions

DRUG

Sildenafil

oral Sildenafil 3 x 20 mg for 90 days

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Kerckhoff Heart Center

    lead OTHER

Principal Investigators

  • Andreas J Rieth, MD · Kerckhoff Heart Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01889966 on ClinicalTrials.gov